2. Search Result
Search Result
Results for "

CDDO

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14909
    Bardoxolone
    10+ Cited Publications

    CDDO; RTA 401

    		 Keap1-Nrf2 Necroptosis Metabolic Disease
    Bardoxolone (CDDO) is a novel nuclear regulatory factor (Nrf-2) activator for the study of chronic kidney disease. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis .
    Bardoxolone
  • HY-126379
    CDDO-2P-Im

    		Apoptosis Cancer
    CDDO-2P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-2P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model .
    <em>CDDO</em>-2P-Im
  • HY-135953
    CDDO-3P-Im

    		Apoptosis Cancer
    CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model . CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R) .
    <em>CDDO</em>-3P-Im
  • HY-15725
    CDDO-Im
    5+ Cited Publications

    RTA-403; TP-235; CDDO-Imidazolide

    		 Keap1-Nrf2 PPAR Ferroptosis Cancer
    CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ .
    <em>CDDO</em>-Im
  • HY-12213
    CDDO-EA
    2 Publications Verification

    CDDO ethyl amide; TP319; RTA 405

    		 Keap1-Nrf2 Cancer
    CDDO-EA is an NF-E2 related factor 2/antioxidant response element (Nrf2/ARE) activator.
    <em>CDDO</em>-EA
  • HY-112671
    CDDO-dhTFEA

    RTA dh404

    		 Keap1-Nrf2 NF-κB Inflammation/Immunology
    CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .
    <em>CDDO</em>-dhTFEA
  • HY-13324
    Bardoxolone methyl
    Maximum Cited Publications
    24 Publications Verification

    RTA 402; NSC 713200; CDDO Methyl ester

    		 Keap1-Nrf2 Autophagy Apoptosis Ferroptosis Cancer
    Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) is a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities, acting as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway.
    Bardoxolone methyl

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: